HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Demand For Vitafusion, L’il Critters Gummy Lines Exceeds Church & Dwight Capacity, Drive Q3 Growth

Executive Summary

Church & Dwight reports strong consumption of its Vitafusion and L’il Critters vitamins drove personal care product division sales up 24.5% and prompted it to use contract manufacturing to meet demand. The firm also adjusted its net sales outlook for the year to 11% and its EPS to $2.79-$2.81.

You may also be interested in...



Church & Dwight Wakes Up L'il Critters Children's Gummy Vitamin Line With Melatonin

Sold online and in stores at Target, L’il Critters Melatonin Gummies are $11.99 for 60, 1.5-mg melatonin gummies for use in children who have trouble falling asleep.

Sales Grow Across C&D's Products And Regions, But Increasing Supply Costs Stunt Income

Raw material supplies slowed during January-March period by catastrophic freeze in Texas and shortage of shipping containers partly due to Suez Canal blockage. "We're absorbing $90 million of incremental costs for the full year,” says CFO Ronald Dierker.

Gummy Vitamin Manufacturing Hurdles Grow With Demand For Novel Formulations

Gummy manufacturing challenges include stability of “decaying” active ingredients, loading all ingredients into limited space and inadequate testing, says Church & Dwight scientist Kristen Farr.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150641

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel